Viking Therapeutics has frequently been highlighted by wall street analysts and financial media outlets as a prominent speculative buyout target within the pharmaceutical sector. Driven by the massive commercial success and promising clinical trial data surrounding its flagship metabolic and obesity drug candidates like VK2735, major multinational drug manufacturers seeking to capture market share in the lucrative GLP-1 treatment landscape have often been rumored by market insiders as potential suitors.